alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
CS243954H

National Center for Chronic Disease Prevention and Health Promotion 

Office on Smoking and Health 

Defining the specific annual investment needed for state comprehensive tobacco control programs 

to implement what we know works to reduce tobacco-related disease and death. 

Surveillance is 

continually monitoring 

attitudes, behaviors, and 

health outcomes over 

time. Strong surveillance 

is the foundation of 

effective public health 

programs.

Evaluation is 

systematically collecting 

information about 

program activities, 

characteristics, and 

results to judge program 

effectiveness. Evaluation 

allows programs to know 

what works and to make 

improvements. 

Surveillance and Evaluation 

Strong surveillance and evaluation systems are essential for 

comprehensive tobacco control programs to understand program 

effectiveness, make decisions, and be held accountable.

These systems can also inform the public about the rapidly 

changing tobacco control environment, including the impact of 

federal product regulation and new products in the marketplace.

Some existing surveillance and evaluation resources include:

• State Youth and Adult Tobacco Surveys

• Behavioral Risk Factor Surveillance System

• National Adult Tobacco Survey

• National Youth Tobacco Survey

• State Tobacco Activities Tracking and Evaluation (STATE) System 

• Youth Risk Behavior Surveillance System 

State tobacco control programs should leverage these resources to 

conduct surveillance and evaluate program activities.

Considerations For Funding Levels

CDC recommends that tobacco control programs use at least10% of 

total annual funding for surveillance and evaluation activities. 

CDC also recommends that tobacco control programs establish 

and maintain the infrastructure they need to ensure surveillance 

and evaluation systems are responsive and flexible to the rapidly 

changing tobacco control environment.

Additional funds may be necessary for more complex surveillance 

and evaluation activities (e.g., evaluating innovative, experimental 

activities).

2014
TABLE 2. Percentage of persons aged 18–64 years who reported receiving influenza or

pneumococcal vaccine, by age and selected high-risk medical conditions — National Health

Interview Survey, United States, 1998*

High-risk condition†

Received influenza vaccine

during previous 12 mos

Ever received

pneumococcal vaccine

18–49 yrs

(n=19,546)

50–64 yrs

(n=6,194)

18–49 yrs

(n=19,011)

50–64 yrs

(n=6,090)

% (95% CI‡) % (95% CI) % (95% CI) % (95% CI)

Ever had Diabetes 31.2 (±5.2) 47.4 (±4.8) 14.6 (±3.9) 24.4 (±4.2)

Asthma or chronic

bronchitis during the

previous year, or ever

had emphysema

21.2 (±2.6) 46.7 (±4.8) 9.8 (±2.4) 29.4 (±4.7)

Ever had a heart

attack, coronary heart

disease, angina, or

other chronic heart

condition

22.2 (±3.1) 44.6 (±3.6) 10.1 (±2.2) 22.3 (±3.2)

Chronic kidney disease

during the previous

year

30.8 (±8.1) 47.0 (±9.5) 15.0 (±6.2) 28.1 (±9.1)

Cancer diagnosed in

previous year or ever

had selected cancers† 

30.9 (±10.2) 38.3(±11.4) 16.0 (±7.6) 23.5 (±9.1)

Liver disease during

the previous year

** - ** - 13.5 (±5.2) 17.4 (±7.7)

None of the above highrisk conditions 14.4 (±0.6) 28.9 (±1.5) 4.5 (±0.4) 8.2 (±1.0)

*n=26,106. Sample sizes might not total 26,106 because persons with unknown vaccination

status were excluded from analysis.

†The prevalences of influenza and pneumococcal vaccination among persons aged 18–64 years

were estimated for those at high risk for complications caused by these infections.

Persons who indicated more than one condition were included in the calculation of

vaccination coverage for each condition reported. Persons categorized as “high risk” for

influenza-related complications self-reported one or more of the following: Ever being

told by a physician they had diabetes, emphysema, coronary heart disease, angina, heart

attack or other heart condition; being diagnosed with cancer in the past 12 months

(excluding non-melanoma skin cancer) or ever being told by a physician they have

lymphoma, leukemia or blood cancer; in the past 12 months being told by a physician they

have chronic bronchitis or weak or failing kidneys; or reporting an asthma episode or

attack in the past 12 months. Persons categorized as “high risk” for pneumococcalrelated complications met the above criteria, excluding asthma, or reported liver disease

during the past 12 months.

‡Confidence interval. 95% CIs were calculated by multiplying the standard error by ±1.96.
§The standard of reliability is RSE <0.3 (where RSE = the ratio of the standard error and

the prevalence). This estimate did not meet that standard, or the denominator was <30. 

**Not included as a high-risk condition for which influenza vaccination is recommended.
(1) Adjusting Price

Base Skim Milk Price for Class I $13.34 CWT 0.965 12.87

Advanced Butterfat Pricing Factor $1.9743 LB 3.5 6.91

Class I Price 19.78

(2) Base Price

Base Skim Milk Price for Class I $10.62 CWT 0.965 10.25

Advanced Butterfat Pricing Factor $1.8023 LB 3.5 6.31

Class I Price 16.56

(3) Change from Base Price per CWT 3.23

(4) Price change per gallon 0.28

(Line (3) divide by 11.63 gallons/cwt)

(5) Price change per half gallon 0.14

Price change per quart 0.07

Price change per pint 0.03

Price change per 12-oz pg. 0.02

Price change per 1/3 qt. (10-oz) 0.02

Price change per half pint 0.02

(6) Price adjustment per gallon 0.28

Price adjustment per half gallon 0.14

Price adjustment per quart 0.07

Price adjustment per pint 0.03

Price change per 12-oz pg. 0.02

Price adjustment per 1/3 qt. (10-oz) 0.02

Price adjustment per half pint 0.02

**No price adjustment is required if the price change per-gallon, in either direction,

is not equal to or greater than +/-$0.0100 (See paragraph (f)(1) of the clause). 

NOTE: Numbers in brackets are negative or decreases, all others are positives or increases. 

Monthly EPA Calculation for Class I Milk (Clause 52.216-9032)

Based on USDA Announcement of Advanced Prices and Pricing Factors

Effective Date: August 2, 2020
No. 11-432.

#### Misty Raley, Individually and as Parent and Next Friend of C. G., W. G., and C. A. G., Minor Children, Petitioner v. Hyundai Motor Company, Ltd., et al.

565 U.S. 1062, 132 S. Ct. 779,

181 L. Ed. 2d 488,

2011 U.S. LEXIS 8664.

November 28, 2011.

Petition for writ of certiorari to the United States Court of Appeals for the Tenth Circuit denied.

Same case below, 642 F.3d 1271.
[Federal Register Volume 63, Number 133 (Monday, July 13, 1998)]
[Notices]
[Page 37558]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-18494]


-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission
[Docket No. TM98-3-49-000]


Williston Basin Interstate Pipeline Company; Notice of Fuel 
Reimbursement Charge Filing

July 7, 1998.
    Take notice that on July 1, 1998, Williston Basin Interstate 
Pipeline Company (Williston Basin), tendered for filing as part of its 
FERC Gas Tariff, the following revised tariff sheets, with an effective 
date of August 1, 1998:

Second Revised Volume No. 1,
Thirtieth Revised Sheet No. 15
Twelfth Revised Sheet No. 15A
Thirty-third Revised Sheet No. 16
Twelfth Revised Sheet No. 16A
Twenty-ninth Revised Sheet No. 18
Twelfth Revised Sheet No. 18A
Twelfth Revised Sheet No. 19
Twelfth Revised Sheet No. 20
Twenty-sixth Revised Sheet No. 21
Original Volume No. 2
Seventy-fourth Revised Sheet No. 11B

    Williston Basin states that the revised tariff sheets reflect 
revisions to the fuel reimbursement charge and percentage components of 
the Company's relevant gathering, transportation and storage rates, 
pursuant to Williston Basin's Fuel Reimbursement Adjustment Provision, 
contained in Section 38 of the General Terms and Conditions of 
Williston Basin's FERC Gas Tariff, Second Revised Volume No. 1.
    Any person desiring to be heard or to protest this filing should 
file a motion to intervene or a protest with the Federal Energy 
Regulatory Commission, 888 First Street, N.E., Washington, D.C. 20426, 
in accordance with Sections 385.214 and 385.211 of the Commission's 
Rule and Regulations. All such motions or protests must be filed on or 
before July 14, 1998. Protests will be considered by the Commission in 
determining the appropriate action to be taken, but will not serve to 
make protestants parties to the proceedings. Any person wishing to 
become a party must file a motion to intervene. Copies of this filing 
are on file with the Commission and are available for public inspection 
in the Public Reference Room.
David P. Boergers,
Acting Secretary.
[FR Doc. 98-18494 Filed 7-10-98; 8:45 am]
BILLING CODE 6717-01-M
(1) Adjusting Price

Base Skim Milk Price for Class I $6.12 CWT 0.965 $5.9058

Advanced Butterfat Pricing Factor $2.2255 LB 3.5 $7.7893

Class I Price $13.6951

(2) Base Price

Base Skim Milk Price for Class I $6.22 CWT 0.965 $6.0023

Advanced Butterfat Pricing Factor $2.2106 LB 3.5 $7.7371

Class I Price $13.7394

(3) Change from Base Price per CWT ($0.0444)

(4) Price change per gallon ($0.0038)

(Line (3) divide by 11.63 gallons/cwt)

(5) Price change per half gallon ($0.0019)

Price change per quart ($0.0010)

Price change per pint ($0.0005)

Price change per 12-oz pg. ($0.0003)

Price change per 1/3 qt. (10-oz) ($0.0003)

Price change per half pint ($0.0002)

(6) Price adjustment per gallon ($0.00)

Price adjustment per half gallon ($0.00)

Price adjustment per quart ($0.00)

Price adjustment per pint ($0.00)

Price change per 12-oz pg. ($0.00)

Price adjustment per 1/3 qt. (10-oz) ($0.00)

Price adjustment per half pint ($0.00)

**No price adjustment is required if the price change per-gallon, in either direction,

is not equal to or greater than +/-$0.0100 (See paragraph (f)(1) of the clause). 

NOTE: Numbers in brackets are negative or decreases, all others are positives or increases. 

Monthly EPA Calculation for Class I Milk (Clause 52.216-9032)

Based on USDA Announcement of Advanced Prices and Pricing Factors

Effective Date: May 1, 2016
(logo)CWCapital

ASSETMANAGEMENT

** **

** **

**Annual Statement asto Compliance**

**For the Period ofJanuary 1, 2018 to December 31, 2018**

 

 

**Bank 2017-BNK5**

 

 

Inaccordance with Item 1123 of Regulation AB and with the requirements detailedin §11.09 of the Pooling and Servicing Agreement (the “Agreement”) forthe above-mentioned CMBS pool, CWCapital Asset Management LLC (“CWCAM”),in its capacity as Special Servicer, is providing this Officer’s Certificatewith respect to the following:

 

(A)      A review of CWCAM’s activities during the period noted above (the “Reporting Period”)and of CWCAM’s performance under the Agreement has been made under mysupervision; and

 

(B)      To the best of my knowledge, based on such review, CWCAM has fulfilled all its obligationsunder the Agreement in all material respects throughout the Reporting Period.

 

Shouldyou have any questions, please do not hesitate to contact us.

 

Sincerely,

CWCapitalAsset Management LLC

/s/James P. Shevlin

JamesP. Shevlin 

President/ChiefOperating Officer

 

 

7501Wisconsin Avenue | Suite 500 West | Bethesda, MD | 20814
Final Listing of Questionnaire Files for Steam Electric Rulemaking Record

Plant ID 04671

Removed 

from Public 

(Non-CBI) 

Docket1

Copyright 

Flag2

File Name Description

04671\04671_HardcopyLog.doc EPA log of hardcopy documents submitted

x 04671\04671_Part A.xls Plant submitted survey file

x 04671\04671_Part B.xls Plant submitted survey file

x 04671\04671_Part C.xls Plant submitted survey file

x 04671\04671_Part D.xls Plant submitted survey file

x 04671\04671_Part H.xls Plant submitted survey file

04671\Certification Statement Plant ID 04671.pdf Plant certification statement

x 04671\Follow-up\Southampton_Power_Station_04671.doc Follow-up material as part of the survey.

x 04671\Follow-up\Southampton_Power_Station_04671.pdf Follow-up material as part of the survey.

x 04671\Supplemental Documents\04671_SH_A5-2 Maps.pdf Plant submitted supplemental files to the survey

x 04671\Supplemental Documents\04671_SH_A5-3_Flow Diagram.pdf Plant submitted supplemental files to the survey

x 04671\Supplemental Documents\04671_SH_D3-1_POND DIAGRAM.pdf Plant submitted supplemental files to the survey

x 04671\04671_Checklist.xls EPA Technical Review Checklist Workbook

04671\04671_Completeness_Checklist.xls EPA Completeness Review Checklist

04671\04671 (09374)_Cover Letter.pdf Plant submitted supplemental files to the survey

1

 Final reviewed survey responses are located in the Steam Electric Technical Questionnaire Database . 

2

 Copyright documents are available from the docket.
ARCHIVED DOCUMENT 

(COVID-19)

The following document is for historical 

purposes and is no longer being 

updated. Please go to the COVID-19 

Vaccination Clinical & Professional 

Resourcesfor more recent information. 

U.S. Department of

Health and Human Services

Centers for Disease 

Control and Prevention
U.S. Department of 

Health and Human Services 

Centers for Disease 

Control and Prevention 

APPENDIX A

COVID-19 Vaccine Communication 

and Confidence Checklist

Use this checklist to promote COVID-19 vaccine confidence among your healthcare personnel.

Activity

1 Give COVID-19 vaccine communication and confidence basics presentation to healthcare personnel.

CDC Resources:

 Building Confidence in COVID-19 Vaccines Among Your Patients: Tips for the Healthcare Team (PowerPoint)

 How to Build Healthcare Personnel’s Confidence in COVID-19 Vaccines (Guide)

2 Hold an initial discussion with 8–10 staff to identify strategies for making vaccine confidence visible.

CDC Resource:

COVID-19 Vaccine Confidence Conversation Starter (Guide)

3 Provide training and education

 Educate all staff about COVID-19 vaccine.

Train healthcare teams about the vaccines, how to build vaccine confidence, and how to have effective 

conversations about vaccines with patients.

CDC Resources:

 COVID-19 Vaccine Basics: What Healthcare Personnel Need to Know (Flyer)

 Building Confidence in COVID-19 Vaccines Among Your Patients: Tips for the Healthcare Team (Flyer)

 Quick Answers to Common Questions People May Ask about COVID-19 Vaccines: Tips for Healthcare 

Professionals (Flyer)

4 Post COVID-19 vaccine educational materials in staff break rooms and common areas in your health facility 

(posters, handouts, FAQs).

5 Post COVID-19 vaccine information blogs and/or articles on your website, intranet, and social media platforms 

(blog posts, social media, videos).

6 Create and publicize a feedback mechanism for staff members to ask questions or receive guidance about 

COVID-19 vaccination (email inbox, phone number, point of contact).

7 Share regular staff updates on COVID-19 vaccination efforts (staff meetings, email blasts).

8 Communicate where, when, and how healthcare personnel will be offered the vaccine. Share any plans to 

support personnel needing time away from clinical care if they are experiencing any expected post-vaccine side 

effects (posters and flyers in break rooms, staff meetings, email blasts).

9 Have conversations with staff about the vaccines, and use strategies identified during staff discussions to make 

vaccine confidence visible in your facility.

CDC Resource:

 COVID-19 Vaccine Confidence Conversation

10 Share testimonials from healthcare personnel who volunteer to speak about why they got vaccinated and 

promote among staff, such as on the intranet or internet, in staff meetings, and on social media (social media, 

blog posts).

11 Recognize healthcare personnel who have been effective vaccine confidence boosters (staff meetings, email 

blasts, social media, blog post).

www.cdc.gov/coronavirus/vaccines

CS322228-A 01/31/21
ACTIO N 

## Swann , Joean n (OST) 

## SIO -llO l 19-01 9 From : Sent : To : Subject : CONTRO LN O Cordov a Dru g Co. , Inc

. [cordovadrug@ctcak.net ] Friday , January14 , 201 1 4:4 8 P M LaHood , Ray(OST ) EA S Cordov a *Cordov a Dru g Co. , Inc. * *Bo x220 * *51 6 Firs t Street * •Cordova , Alask a 99574 * *(9e7 ) 424-324 6 Fax(907 ) 424-3245 * *emai l cordovadruglSctcak.ne t <mailto : cordovadrugiSctcak . net> * *Januar y14 , 2011 * *Alask a Airline s * *Re : Essentia l Ai r Servic e * '.. J

e n C O

*A s a busines s owne r i n a communit ytha t i s serve d b yAlask a Airline s m ybusines s an

d I rel y heavil yo n th e dail yje t ser^vic e yo u provide . Th e healt han d welfar e o f manyo f th e patient s tha t ar e m

ypr^escription customer s depend o n th e timel ydeliver^yo f prescriptio n medications . Withou t th e dail ydeliver yb yyou r airlin e o f thes e commoditie s I fea r tha t i t coul d jeopardiz e thei r health . Thi s coul d resul t i n hospitalization , o r worse , Medevac . M ybusines s an

d m yfamil yals o rel yo n you r dail yservic e t o trave l fo r medica l reason s an d t o visi t love d one s durin g time s o f poo r healt ho r emergency . W e appreciat e immensel ytha t yo u offe r thi s servic e an d I personally , an d a s a busines s owner , hop e tha t i t ca n continu e withou t interruption . * *Sincerely , *Davi d A . O'Brie n Rph * *Owner *
No. 11-6090.

#### Michael Anthony Evans, Petitioner v. Adrienne Hernandez, et al.

565 U.S. 984, 132 S. Ct. 510,

181 L. Ed. 2d 360,

2011 U.S. LEXIS 7808.

October 31, 2011.

Petition for writ of certiorari to the Court of Appeals of Texas, Thirteenth District, denied.
Page 3 of 3
EX-10.6



 Exhibit 10.6 

Mandate Agreement 

between 
 Auris Medical
AG, Basel 
 and 

Altamira Pharma GmbH, Zuchwil 
 Mandate

 Auris Medical AG (“AMAG”) herewith instructs and mandates Altamira Pharma GmbH (“APG”) to provide support to AMAG in the strategic
management of the business and in selected operational tasks. 
 Fees 

AMAG shall pay to APG a monthly fee of CHF 20’000.—, including VAT, and a lump-sum expense allowance of CHF 600.—. Expenses in excess of the
lump-sum allowance incurred in relation with the execution of the mandate shall be charged separately and against receipt. 
 Confidentiality 

APG shall maintain secrecy over any and all business secrets and confidential information supplied based upon this agreement or of which it has obtained
knowledge otherwise. This confidentiality obligation shall apply for the duration of this mandate and three years after its termination. 
 No
confidentiality obligation shall apply if and to the extent that information concerned 
  

	•	 	is in the public domain, or 

  

	•	 	has become of public domain without act or failure of the concerned contractual party, or 

  

	•	 	was / has been obtained rightfully by a third party, or 

  

	•	 	already was in possession of the concerned contractual party. 

 Upon termination of this agreement, APG shall
immediately return all documents, files, letters, schemes, equipment, products, software etc. belonging to AMAG, as well as copies and electronic records thereof, to AMAG. 

Non-competition clause 
 During this mandate, APG
undertakes not to perform any activities which are directly or indirectly competing with AMAG. 

  
 1 








 Intellectual Property Rights 

Inventions, creations, works and other Intellectual property are owned by AMAG to the extent as they are created in the performance of APG’s contractual
obligations. 
 Duration of the Mandate 
 This mandate
is entered into for an indefinite period of time. Either party may terminate the agreement in writing with a 3-months’ notice period, with effect as to the end of a month. 

Miscellaneous 
  

	•	 	If any provision of this agreement is held to be invalid, such invalidity shall not affect any other part of this contract. 

  

	•	 	The place of jurisdiction is the City of Basle. 

  

			
	Basle, 4 January 2011	  	Zuchwil, 4 January 2011
		
	[Signature]	  	[Signature]
		
	Auris Medical AG	  	Altamira Pharma GmbH


  
 Page 2
ID Descriptor L* a* b* c h dL* da* db* dEcmc*

Standard 21029 STANDARD 60.00 3.70 18.55

Tolerance

1

2

3

4

5

6

7

8

9

COMMENTS: NUMBERS ARE FOR REFERENCE ONLY 

Equipment Type HUNTER ULTRA SCAN PRO Setting Mode: Specular Included - Reflectance

UV Filter – OUT UV Lamp OFF

DLA/NAVY SHADE TOLERANCE PROJECT April 5, 2021

Fabric Nomenclature CLOTH, TWILL, FLAME RESISTANT NAWC PD 4672-16-02

(CLASS 2)

Shade Number KHAKI 3729 Piece/Roll Number 21029
EXHIBIT 35.1








ANNUAL SERVICER COMPLIANCE STATEMENT PURSUANT TO ITEM 1123 OF REGULATION AB





CARMAX BUSINESS SERVICES, LLC








The undersigned, a duly authorized officer of CarMax Business Services, LLC, as Servicer pursuant to Section 3.10 of the Sale and Servicing Agreement dated as of July 1, 2017 (the "Sale and Servicing Agreement") among CarMax Auto Owner Trust 2017-3, as Issuer (the "Issuer"), CarMax Auto Funding LLC, as Depositor, and CarMax Business Services, LLC, as Servicer (the "Servicer"), does hereby certify that:





|   |                                                                                                              
|-- | -------------------------------------------------------------------------------------------------------------
|1. | CarMax Business Services, LLC is, as of the date hereof, the Servicer under the Sale and Servicing Agreement.




|   |                                                                                      
|-- | -------------------------------------------------------------------------------------
|2. | The undersigned is duly authorized to execute and deliver this Officer's Certificate.




|   |                                                                                                                                                                                                                                                                                                                                                                                                                            
|-- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|3. | A review of the activities of the Servicer during the period beginning on July 26, 2017 and ending onFebruary 28, 2018and of the Servicer's performance under the Sale and Servicing Agreement was made under my supervision.  To the best of my knowledge, based on such review, the Servicer has fulfilled all of its obligations under the Sale and Servicing Agreement in all material respects throughout such period.







Capitalized terms used in this certificate and not otherwise defined herein have the meanings assigned to them in the Sale and Servicing Agreement.





IN WITNESS WHEREOF, the undersigned, a duly authorized officer of the Servicer, has duly executed this Officer's Certificate this 18th day of May, 2018 .





CARMAX BUSINESS SERVICES, LLC





/s/ Enrique Mayor-Mora


Enrique Mayor-Mora


Vice President and Treasurer
Imperial County Air Pollut ion Control District Rule 212

21 2

- 1 RULE 212 ANNUAL RENEWAL (Adopted 11/19/85; R evised 9/14/99)

A permit issued pursuant to these Rules is good for the calendar year for which it is issued. If the article, machine, Equipment or contrivance for which a permit is issued is

to continue in use or operation, a new permit must be issued for each calendar year, or part thereof, during which said article is in operation.